- Home
- CNC vs DMAC Comparison
CNC vs DMAC Comparison
Compare CNC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNC
- DMAC
- Stock Information
- Founded
- CNC 1984
- DMAC 2000
- Country
- CNC United States
- DMAC United States
- Employees
- CNC N/A
- DMAC N/A
- Industry
- CNC Medical Specialities
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- CNC Health Care
- DMAC Health Care
- Exchange
- CNC Nasdaq
- DMAC Nasdaq
- Market Cap
- CNC 28.1B
- DMAC 178.0M
- IPO Year
- CNC 2001
- DMAC N/A
- Fundamental
- Price
- CNC $30.00
- DMAC $4.25
- Analyst Decision
- CNC Buy
- DMAC Strong Buy
- Analyst Count
- CNC 17
- DMAC 2
- Target Price
- CNC $62.63
- DMAC $8.00
- AVG Volume (30 Days)
- CNC 15.5M
- DMAC 341.9K
- Earning Date
- CNC 07-25-2025
- DMAC 08-06-2025
- Dividend Yield
- CNC N/A
- DMAC N/A
- EPS Growth
- CNC 33.19
- DMAC N/A
- EPS
- CNC 6.72
- DMAC N/A
- Revenue
- CNC $153,266,000,000.00
- DMAC N/A
- Revenue This Year
- CNC $23.63
- DMAC N/A
- Revenue Next Year
- CNC $0.61
- DMAC N/A
- P/E Ratio
- CNC $4.46
- DMAC N/A
- Revenue Growth
- CNC 7.22
- DMAC N/A
- 52 Week Low
- CNC $30.00
- DMAC $3.19
- 52 Week High
- CNC $80.59
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- CNC 14.74
- DMAC 58.21
- Support Level
- CNC $31.78
- DMAC $3.58
- Resistance Level
- CNC $33.41
- DMAC $3.88
- Average True Range (ATR)
- CNC 1.46
- DMAC 0.26
- MACD
- CNC -1.50
- DMAC 0.05
- Stochastic Oscillator
- CNC 0.09
- DMAC 97.74
About CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.